Therapeutic exon skipping for dysferlinopathies?

Area of Science:

• Genetics
• Molecular Biology
• Neuromuscular Disorders

Background:

• Antisense-mediated exon skipping is a validated therapeutic strategy for Duchenne muscular dystrophy (DMD).
• This approach reframes dystrophin transcripts by hiding exons, restoring the reading frame to produce partially functional proteins.
• The redundancy of the dystrophin protein's central rod domain supports this therapeutic strategy.

Purpose of the Study:

• To investigate the applicability of exon skipping for dysferlinopathies, including limb-girdle muscular dystrophy type 2B (LGMD2B), Myoshi myopathy (MM), and distal myopathy with anterior tibial onset (DMAT).
• To analyze dysferlin protein domains and DYSF gene mutations to identify promising exon targets for therapeutic skipping.
• To assess the feasibility of using antisense oligonucleotides (AONs) for DYSF exon skipping.

Main Methods:

• Analysis of dysferlin protein domains and known DYSF mutations.
• Identification of target exons within the DYSF gene for antisense oligonucleotide (AON)-mediated skipping.
• Experimental validation of AONs to induce efficient skipping of specific DYSF exons.

Main Results:

• Dysferlin protein, crucial for muscle membrane repair, contains essential N- and C-terminal domains and a transmembrane domain.
• The existence of mildly affected patients with large deletions suggests that internally deleted dysferlin proteins can retain functionality.
• Efficient skipping of four DYSF exons was readily achieved using AONs, indicating feasibility comparable to DMD exon skipping.

Conclusions:

• Exon skipping is a potentially viable therapeutic strategy for dysferlinopathies (LGMD2B, MM, DMAT), similar to its application in DMD.
• The analysis of DYSF gene structure and mutations supports the identification of suitable exon targets for AON-mediated therapy.
• This study demonstrates the straightforward applicability and feasibility of DYSF exon skipping, paving the way for new therapeutic avenues.